Background: Current therapeutic strategies for type 1 (T1DM) and type 2 diabetes mellitus (T2DM) rely on increasing or substituting endogenous insulin secretion in combination with lifestyle changes. b-cell regeneration, a process whereby new b-cells arise from progenitors, self-renewal or transdifferentiation, has the potential to become a viable route to insulin self-sufficiency. Current regeneration strategies capture many of the transcriptomic and protein features of native b-cells, generating cells capable of glucose-dependent insulin secretion in vitro and alleviation of hyperglycemia in vivo. However, whether novel b-cells display appreciable heterogeneity remains poorly understood, with potential consequences for long-term functional robustness.
INTRODUCTION
By 2045, it is predicted that 9.9% of the global adult population will live with type 1 (T1DM) and type 2 diabetes mellitus (T2DM) [1] . T1DM is generally associated with almost complete b-cell loss and dependency on insulin injections [2] . T2DM arises as a result of insufficient insulin secretion from pancreatic b-cells and/or impaired sensitivity of the liver, muscle and adipose tissue to insulin action [3] . Conventional therapeutic approaches rely on increasing insulin output, improving insulin sensitivity and during later stages of the disease, insulin replacement. While these treatments are effective when combined with diet and exercise, maintaining good glycemic control throughout the lifespan can be difficult. In patients who become non-responsive to therapy and/or struggle with hypoglycemia following insulin supplementation, islet transplantation is a therapy of choice, although limited donor supply and the need for immunosuppression [4, 5] make this a third-line option. Therefore, much recent research effort has been focused on b-cell regeneration, with the hope of producing a virtually unlimited supply of functional b-cells.
The manipulation of human embryonic stem cells (hESC) [6, 7] and induced pluripotent stem cells (iPSC) [8] has given rise to numerous studies describing generation of b-cells derived from pluripotent nonpancreatic progenitors. Newly-generated b-cells forming clusters were derived in vitro and, once transplanted into diabetic mice and rats, were able to mature, survive for a limited period of time, secrete insulin in response to glucose load and correct the hyperglycemia [9e15]. An alternative approach involves lineage reprogramming of non-endocrine cells in vivo (i.e. pancreatic exocrine, gastrointestinal), initiated by adenoviral-or TetO-driven polycistronic re-expression of the islet endocrine markers Ngn3, Pdx1 and Mafa [16e19]. These studies described generation of insulin-positive cells exhibiting some b-cell morphological and functional traits. Although these b-like cells were able to manifest insulin secretion in vitro and alleviate hyperglycemia in diabetic mice, their phenotype remained relatively immature. A similar phenotype, albeit with improved b-cell maturity, was reported following FOXO1 inhibition in human gut organoids [20] , highlighting this tissue as a promising pool of b-cell progenitors. Capitalizing on the islet plasticity concept, adult glucagon-secreting a-cells were used as a source of b-cells via transdifferentiation in vivo. The process could be initiated by inactivation of both Arx and Dnmt1 [21] or Arx alone [22] , g-aminobutiric acid (GABA) [23] or artemether treatment [24] (with caveats-see later), which lead to development of neo-b-cells with gene 1 and protein expression patterns resembling normal b-cells in vivo.
Very recent studies have shown that overexpression of PDX1, MAFA and NKX6-1 can also transform human adult a-cells into insulinsecreting cells able to form pseudoislets and with nearly normal insulin secretion in vitro [25] , suggesting that transdifferentiation per se may be valuable route to replenishing bcells. Current efforts are focused on increasing b-cell number, maturity, function and post-transplantation survival. The proportion of cells undergoing transformation to b-cells varies, depending on the experimental setting, but it does not include all cells targeted with the transformation/rederivation protocol. Once directed on a path towards b-cell identity, many insulin-positive cells stay polyhormonal, coexpressing glucagon together with insulin and often, somatostatin as well. Confirmation of b-cell phenotype depends mainly on measuring b-cell-specific gene and protein expression, without taking into account the subtle differences that exist among different b-cell subpopulations, as shown by studies of b-cell heterogeneity. In addition, a recent transcriptomic profiling study of emerging b-cells has highlighted the need to address the developmental intricacies that define regenerated cells throughout the differentiation protocol [26] .
Furthermore, functioning of the new b-cells is often assessed only by the insulin response to glucose and/or other secretagogues, and the success in reducing hyperglycemia in vivo. Also, more work needs to be focused on increasing b-cell survival after transplantation and elucidating the underlying mechanisms. Finally, current protocols generate islet-like clusters, but the complex islet structure and the intercellular connectivity have yet to be recreated [27e29]. Addressing these limitations, together with translating the findings from mouse to human, might be the key to successful reconstruction of b-cells within novel islets.
OVERVIEW OF b-CELL REGENERATION EFFORTS
All in vitro hESC-and iPSC-derived b-cell regeneration protocols were devised based on processes imitating normal pancreatic and islet development. Functional b-cells start developing from the embryonic definitive endoderm, undergoing changes taking them through formation of the primitive gut tube, posterior foregut and pancreatic endocrine progenitors, and finishing with specification of each individual islet cell type [30, 31] . For regenerative purposes, b-cell differentiation protocols are divided into four to seven stages, each driven by application of molecular stimuli and inhibitors able to turn on/off expression of stage-specific transcription factors until a b-like cell population is formed [9e15]. Novel b-like cells express key b-cell markers including PDX1, MAFA and NKX6-1 [9, 12, 19] , while protein signatures confirm the presence of insulin and formation of insulin granules [9, 15, 16, 21] , followed by aggregation of islet-like clusters [15, 17, 25] . Concentration-dependent responses to glucose are also present, with evidence of biphasic insulin secretion [12, 15, 25] . Subsequent transplantation of the b-cell clusters under the kidney capsule in diabetic mice leads to a gradual increase of circulating human Cpeptide in response to glucose, as well as amelioration of hyperglycemia for upwards of a year [15, 19, 22] . Taken together, current approaches for generating novel human b-cells in vitro coupled with further maturation in vivo in mice show high resemblance to normal bcell phenotype, although the functional quality lags (slightly) behind that of isolated human islets. Lineage reprogramming of non-endocrine cell populations in vivo driven by re-expression or ectopic expression of Pdx1, Ngn3 and Mafa resulted in rapid development of insulin-positive cells in the pancreatic ducts [16, 18] , the intestinal crypts [17] and the stomach epithelium [19] . Using adenoviral transduction and tetracycline induction strategies, these studies showed that the combination of the three transcription factors is essential in driving adult gastrointestinal extra-islet cells toward a b-cell lineage. Insulin-positive cells derived this way develop genetic and protein features of b-cells, lose expression of precursor markers and are able to form isletresembling structures. As seen with other b-cell regeneration approaches, a significant improvement in blood glucose levels was achieved in diabetic mice in all cases. Importantly, similar reprogramming was achieved in bioengineered organoids and transplantation of these structures into diabetic mice also led to improved glucose tolerance [19] .
Regeneration of b-cells can occur as a result of a-to b-conversion, as reported after b-cell loss [32e34]. Abrupt and near-total ablation of bcells in mice initiated b-cell regeneration occurring not as a result of self-renewal, but instead due to downregulation of a-specific Arx and Dnmt1 and ensuing a-to b-transdifferentiation [21, 32] . Islets from T1DM donors also showed downregulation of their a-cell profile, with cells expressing less ARX and exhibiting insulin presence [21] . The new b-cells generated this way showed electrophysiological responses to glucose (when dispersed into single cells), with glucosestimulated insulin secretion (GSIS) patterns resembling those of native b-cells. Similar features were described in a-cell-derived b-like cells arising due to Arx inactivation [22] and GABA administration [23] in mice with overt diabetes, with occurrence of repeated cycles of b-cell hyperplasia and significant improvements in glucose tolerance. In light of contradicting studies reporting that GABA or artemether have no effects on b-cell regeneration using different reporter models [35, 36] , these data require careful consideration. Human a-to b-like conversion can also be driven by overexpression of PDX1, MAFA and NKX6-1 [25] , enabling robust GSIS from the transformed a-cells.
Human studies employing high-throughput small molecule screening (HTS) [37] showed that small molecule inhibitors, such as harmine, are able to trigger b-cell proliferation in vitro and in vivo by inhibiting dualspecificity tyrosine-regulated kinase (DYRK) and transforming growth factor beta superfamily (TGFbSF) signalling [38] . The b-cells derived this way did not show dedifferentiation, but rather had abundant bcell-specific gene and protein expression and showed satisfactory but non-optimal GSIS. Notably, the results were obtained from islets of both healthy and individuals with T2DM. Along similar lines, GABA was shown to trigger b-cell proliferation in rats, with the new b-cells possessing a distinct transcriptomic signature [39] . A summary of the approaches used for b-cell regeneration is shown in Figure 1 .
A consistent finding in all above-mentioned studies is that regenerated b-cells show hallmarks of their native counterparts and can restore normoglycemia in rodent models, but compromises exist in terms of electrical activity, metabolism, survival and insulin secretion. This might limit application in the clinical setting where regenerated b-cells will be expected to perform in patients spanning different ages, BMI, genetic backgrounds and genders [40] .
of glucose-sensing mechanisms. However, the dynamic range of glucose responsiveness and fine-tuning of insulin secretion is still inferior to that detected in normal (native) b-cells.
The performance of the novel cells is assessed by their insulinsecreting ability and Ca 2þ responses in vitro, as well as by their glucose-lowering efficacy in diabetic mice. Static and dynamic GSIS in vitro from isolated differentiated cells and cell clusters showed dose-dependent insulin responses to rising concentration of glucose (11e20 mM glucose) and/or other stimuli (KCl, glibenclamide, Exendin-4, L-arginine) [15, 19] . Patterns of first and second phase insulin secretion were observed [15, 25] , indicating functional insulin granule biogenesis and trafficking, although insulin levels failed to match those of isolated human islets. In addition, Ca 2þ signaling traces from individual cells reflected those in mature human b-cells, but were delayed and with lower amplitude. Taken together, these findings are highly encouraging, but beg the question: if regenerated b-cells have the necessary stimulus-sensing and secretory machinery in place, what else is missing? While impressive data exists on the single-cell transcriptomic landscape of developing/mature native b-cells [41e43] and hESC-derived pancreatic progenitors [44] , the influence of the islet/tissue/in vivo environment remains poorly understood. Most work to date has shown that regenerated b-cells only reach full potential when engrafted in vivo [12, 15, 19, 22] [29, 45] , which is reflected at the level of insulin secretion [46, 47] , insulin content and granule morphology [48, 49] . In addition, differences in intraislet b-cell electrical activity and metabolism are also present [50, 51] .
Differential gene and protein signatures
Studies in rodents and humans have identified b-cell subpopulations based on differential expression of specific gene and protein markers [52e56], insulin granularity [57, 58] , and transcriptomic profile [42, 43] . Innovative promoter imaging showed that expression of Pdx1 and Ins is heterogeneous and reflects the maturity level and proliferative capacity of b-cells. A subgroup of b-cells in human and mouse islets, as well as MIN6 cells, were found to be Pdx1 þ /Ins þ , and these cells actively secreted insulin, indicating maturity [56] . Another subgroup was represented by more immature Pdx1 þ /Ins low b-cells, which were highly proliferative [56] . The study also showed that immature Pdx1 þ /Ins low cells have the ability to become mature and secrete insulin without dividing, suggesting that immature cells are potentially a reservoir for more actively-secreting b-cells, should the demand arise [56] . Flow cytometry analyses stratified b-cells from MIP-GFP mice, which express green fluorescent protein (GFP) under the Ins1 promoter, into three different groups: cells with high, medium and low GFP brightness and granularity, indicative of differences in insulin gene expression [57] . Low GFP/low granularity b-cells with an immature profile were dominant in young mice, suggesting that age could be a factor imparting heterogeneity. Differences can also arise from the insulin mRNA expression and proinsulin content, as observed in this likely reflects transition from a state of active insulin secretion to a state of stress recovery under the UPR program in which insulin production is decreased [60] . Whether or not similar dynamics exist in neo-b-cells or islet-like structures is poorly understood, yet might be important to impart robustness and plasticity on the population.
Moreover, strategies for regenerating b-cells, especially in T2DM patients, should take into consideration the possibility that these differences could be reintroduced in the newly-emerging cells under metabolic stress. Next-generation sequencing and lineage-tracing revealed the presence of Urocortin-3 (Ucn3)-negative cells arising from a-cells at the islet periphery, but exhibiting traits of immature b-cells (so called "virgin" b-cells) [52] . The presence of these cells in mice and human neonatal islets is reassuring, as it indicates a highly-conserved process whose potential could be harnessed in autologous b-cell regeneration. The presence of a protein maintaining the islet 3D structure called Flattop (Fltp) classified b-cells as either Fltpþ or Fltp-cells [53] . Fltpþ cells bear most of the markers of mature b-cells, but have low proliferation potential, whereas Fltp-cells are immature and highly proliferative.
Thus, confirmation of Fltp presence/absence in newly regenerated bcells would be a useful initial indicator of heterogeneity. Single-cell mass cytometry has provided compelling data on the qualities of different b-cell subpopulations in human islets, based on their protein footprint [41] . It identified C1, C2 and C3 b-cell clusters, each associated differently with proliferation (more present in C2 and C3), maturity (higher insulin and PDX1 in C1), age and T2DM (characterized with a C2 decline). For a more complete list of b-cell molecular screening studies refer to reviews [61e63].
Functional diversity
The introduction of modeling [64, 65] to islet biology revealed the dynamics of b-cell intercellular networks and the characteristics of particular cells governing it. Optogenetic silencing during live Ca 2þ imaging showed the existence of 'hubs'eb-cells able to respond early to glucose stimuli and guide but not completely control the activity of the b-cell complement [50] . Hubs are relatively immature b-cells, with low Pdx1 and Nkx6-1 expression, but with highly-active mitochondria, prone to lipotoxic and pro-inflammatory attacks, in keeping with their low ER content [50] . Computational modelling of the electrical activity in mouse and human islets indicated species-specific differences in hub activity, with human hubs being potentially more susceptible to metabolic insults [66] . Intravital studies in zebrafish and mice have shown the presence of analogous cells, able to coordinate the activity of their neighbors [67] . Finally, using optogenetic excitation, different islet regions were shown to disproportionally regulate the function of the b-cell network [51] . It should be noted that such cell types are likely to overlap, since the techniques used describe subpopulations belonging to a distribution of cells spanning similar characteristics (e.g. maturity status, metabolism).
in ensuring survival, adaptability and resistance of b-cells to failure. Different responsiveness and thresholds allow b-cells to fine-tune responses to changing stimuli and ultimately, might prolong function and ensure survival of newly regenerated b-cells. This is an important feature that regenerated b-cells currently lack and which could contribute to limited function and survival. It should therefore not be ignored but integrated into regenerated b-cells.
Islets as the 3D scaffold promoting b-cell heterogeneity, survival and function
Islet architecture is a dynamic niche, which undergoes constant remodeling. Individual b-cells are thus exposed to a different microenvironment over time, altering their function [69] . In mouse islets, regional differences in membrane potential and electrical coupling have been observed between b-cells in the core and those at the periphery, indicating the presence of functional heterogeneity [69e72]. Additionally, heterogeneity in insulin secretion capacity has been observed depending on location and density of blood vessels [73, 74] , and b-cells target the release of insulin granules toward the vasculature [75] . Indeed, islets are highly-vascularized structures, with blood flow and vascularization representing important adaptive components in response to demand [76, 77] . Furthermore, species differences exist in the proportion of different endocrine cell types, as well as their localization relative to one another. Mouse islets contain w80% b-cells, with a-cells arranged at the periphery, probably reflecting the inner/outer blood flow pattern [78] and orientation of intercellular feedback loops [79] . By contrast, human islets contain w50% b-cells, with a tertiary folding step encouraging heterotypic cell contacts with a-cells [80, 81] . Evidently, regenerated b-cells are likely to benefit from the specific endocrine arrangement, as well as from the association with other islet components, including the extracellular matrix (ECM) and the vascular network (Figure 3 ).
a-cells
Glucagon is an important counter-regulatory hormone, which prevents potentially dangerous drops in blood glucose induced by insulin. At low glucose concentration, a-cells secrete glucagon, which stimulates hepatic gluconeogenesis and release of glucose into the circulation [82] . Species diferences exist, with data indicating that glucagon paradoxically promotes insulin secretion in humans, most likely via direct effects on b-cells, as well as via somatostatin release from d-cells [83e85] . Although a-cells normally reduce secretion as glucose levels reach 5 mM, glucagon secretion has been observed even at 20 mM glucose [86, 87] . A rise in glucose may stimulate glucagon release by activating ER Ca 2þ stores, priming b-cells to respond to impending hyperglycemia [83, 84, 88] . In human islets, glucagon receptor activation in b-cells is required to amplify insulin secretion [84] . Furthermore, parasympathetic nerve innervation is more sporadic in humans compared to rodents, with acetylcholine derived from a-cells rather than from neurons, as in mice [89] . At basal glucose, acetylcholine is released and subsequently stimulates insulin secretion, thereby preparing b-cells for a rise in glucose [89, 90] . However, acetylcholine can also indirectly inhibit insulin secretion through activation of somatostatin release [90] . From this, it can be envisaged that, rather than inhibiting regenerated b-cell function, inclusion of a-cells with the correct phenotype might facilitate proper responses to hypoglycemia and amplify insulin release.
d-cells
Another "master inhibitor" hormone is d-cell-derived somatostatin, which downregulates both aand b-cell activity. Comprising only w5% of mouse and human islets, d-cells nonetheless make large contributions to glucagon and insulin secretion. Somatostatin secretion ramps up in response to glucose stimulation, during which time it inhibits glucagon and exerts tonic influence over insulin release [83] . Somatostatin release is stimulated by a paracrine mechanism involving UCN3 co-secreted with insulin from b-cells [91] . Notably, somatostatin secretion is pulsatile, trailing insulin peaks by w30 s, probably reflecting the kinetics of UCN3 [91, 92] . Although suppression of insulin at high glucose seems counterintuitive, d-cell/b-cell interactions represent an intrinsic "buffer" to prevent insulin hypersecretion and rebound hypoglycemia [83] . d-cell morphology in mice is neuron-like with long, protruding arms for increased cell contacts, while in humans d-cells tend to be more interspersed, suggesting a more intimate somatostatinergic regulation of aand b-cell function [83] . As such, d-cells are not only critical for glucose counter-regulation, but might also be important for restraining activity of regenerated b-cells during increased demand, alleviating UPR-initiated stress.
Stromal cells
The islets are home to resident stromal cells such as stellate cells, fibroblasts and endothelial cells. These supportive cells secrete growth factors and ECM-regulating proteins, contributing to extracellular signaling. Endothelial cells promote angiogenesis and their role in regulating islet function and survival has been well documented [93] .
During development, the vasculature is instructive for b-cell and ultimately islet specification [94, 95] . Resident endothelial cells are also required for angiogenesis in newly-formed islets, as well as for connecting the islet to the host endothelium following transplantation [93, 96, 97] . The secretome of endothelial cells includes fibroblast growth factor-2 (FGF-2) and hepatocyte growth factor (HGF), which have been shown to induce b-cell proliferation (HGF) and improve insulin secretion (FGF-2) [98e100]. Further demonstrating the importance of stromal cells during transplantation are studies in islets co-cultured with mesenchymal stromal cells (MSCs), fibroblasts or endothelial cells, which show increased insulin secretion and improved survival [101e105]. Factors secreted by MSCs include C3a, annexin A1, and stromal cell-derived factor (SDF-1), which protect against cytokine-induced apoptosis after transplantation, increase graft survival and improve blood glucose levels in diabetic mice [102] . It will be worth revisiting such studies to determine whether stromal-b-cell interactions improve maturation/stress status, heterogeneity or both. . Previous evidence has shown that endothelial cell-derived collagen IV potentiates insulin secretion through b-cell a1b1 integrins [112] . Mice with b-cell-specific b1 integrin knockout exhibit a decrease in b-cell mass and proliferation [113] , suggesting that establishment of isletematrix interactions is essential for b-cell development. In addition, the matrix might be important in regulating b-cell heterogeneity: expression of a6b1 integrin varies in b-cells, reflecting heterogeneity in their spreading behavior on matrix cultures [108] . Matricellular components have been shown to exert specific regulatory effects on islet adhesion, survival and function [114] . Human islets cultured in collagen I and IV have increased insulin, GLUT2 and GCK gene expression, whereas fibronectin is more important for insulin release [114] . Matricellular structure further protects islets by influencing immune activation, islet infiltration with immune cells and ensuing b-cell destruction [115, 116] . Restoring islet-ECM interactions might therefore provide an additional mechanism to preserve tissue architecture and support the function of regenerated b-cells.
AVENUES TO RESTORING FUNCTION IN REGENERATED

b-CELLS
Heterogeneity is not the only mechanism that dictates viability and function of synthetic b-cells, but it could provide a more solid foundation for introducing plasticity and robustness into islet-like structures. Moreover, missing b-cell subpopulations should be reestablished according to the timeline during which they appear in the islet during development.
Balancing b-cell heterogeneity
Establishing robust glucose responsiveness and insulin secretion is the major goal when producing regenerated b-cells. Recreating a degree of heterogeneity is likely to facilitate this by allowing newly-formed cells to be more dynamic and robust when present in islet-like structures. Indeed, heterogeneous populations might impart improved recovery from ER stress by allowing b-cells to temporarily opt out of insulin secretion should UPR occur. This will become an increasingly important concept as regenerated b-cells are produced with ever higher insulin-secretory capacity. Moreover, metabolic stress expected to occur naturally during transplant-recipient ageing, is likely to be better compensated if grafts contain immature cells capable of undergoing proliferation. This might boost insulin secretion across the population without driving individual cells into hypersecretion and ER stress. Subpopulations with highly secretory characteristics could also be harnessed, but caution should be extended to avoid exhaustion and eventual failure. In this regard, a balance of different b-cell subpopulations spanning immature / mature is likely to be more important to support insulin secretion while maintaining functional robustness.
How can such heterogeneity be achieved in regenerated b-cells? One potential way is to integrate b-cells with different levels of maturity, proliferative potential and secretory/metabolic capacity at time points relative to when they first appear in the islet. This is likely to be challenging, however, since native b-cells tend to lose these heterogeneous characteristics once dissociated, meaning that regenerated b-cells may never attain them in the first place. A possible solution is to mimic the 3D islet architecture by integration of islet cells that maintain b-cells, such as a-cells, d-cells, stromal cells as well as the extracellular matrix (ECM) (see below).
Balancing islet architecture
Establishing the islet architectural components will be important to mimic the islet niche that might contribute to maintenance of heterogeneity and function of regenerated b-cells ( Figure 3 ). Glucose homeostasis does not solely depend on b-cells, but rather on the overall balance between insulin and other counter-regulatory hormones. For example, aand d-cells are essential to monitor b-cell secretion, ultimately preventing hypersecretion and stress while allowing replenishment of insulin and avoiding hypoglycemia. On the other hand, stromal cells and the extracellular matrix are essential to create a microenvironment supportive of growth while maintaining tissue architecture. Several studies have shown that islet function declines in vitro, which may be due to the loss of b-celleb-cell interactions, indirect interactions with other cell types, and inappropriate extracellular signaling [69, 107, 117] . Therefore, promotion of cellecell interactions and cellematrix interactions will be essential to establish functional heterogeneity and therapeutic use of regenerated b-cells.
Recent studies using decellularized pancreatic scaffolds show the potential of such approaches to increase maturation and function of hESC-derived b-cells [118] . Lastly, next generation tools, such as CRISPR genome editing, could be used to impart specific characteristics onto b-cells [119] before their inclusion in the islet.
SUMMARY -GOING FORWARD
Replenishing b-cells after their numbers have been decimated (in the case of T1DM) or once their function has deteriorated beyond remission (occurring in T2DM) is still a revolutionary concept. A number of impressive studies describe novel b-cells with adequate b-cell phenotype, glucose-sensing and insulin-secretory properties, and with the potential to form islet-like structures. However, their proliferative potential, maturity, age/time/demand-dependent distribution, as well as diversity of function remain inferior to those of native b-cells. These differences might reflect the regeneration protocol used, the limited plasticity of the newly-derived b-cells, or the method by which regenerated cells are encapsulated and 
